Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis

V. Sheth, M. Labopin, J. Canaani, L. Volin, A. Brecht, A. Ganser, J. Mayer, H. Labussière-Wallet, J. Bittenbring, R. Shouval, B. Savani, M. Mohty, A. Nagler,

. 2019 ; 54 (4) : 531-539. [pub] 20180807

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20022793
E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 1 rokem
Freely Accessible Science Journals od 1997 do Před 1 rokem
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 30087463
DOI 10.1038/s41409-018-0288-0
Knihovny.cz E-zdroje

FLAMSA followed by sequential reduced intensity conditioning and treosulfan/fludarabine are frequently used conditioning approaches used in centers of the European Society for Blood and Marrow Transplantation (EBMT) for older patients with acute myeloid leukemia (AML). It is currently unknown whether any of these regimens is superior to the others in terms of disease control and toxicity. Using the Acute Leukemia Working Party/EBMT multicenter registry we compared the outcomes of AML patients 45-65 of age transplanted between the years 2007 and 2016. A total of 629 patients were included in the analysis: 281 in the Treo/Flu group, 203 in the FLAMSA/TBI group, and 145 in the FLAMSA/Busulfan group. In multivariate analysis, FLAMSA/TBI conditioned patients had a decreased risk of relapse (hazard ratio (HR) = 0.43; 95% confidence interval (CI), 0.25-0.75; p = 0.002) and superior leukemia-free survival (HR = 0.67; 95% CI, 0.45-0.98; p = 0.042) compared to Treo/Flu conditioned patients. Rates of acute graft-versus-host disease (GVHD) were significantly higher in the FLAMSA/TBI group compared to the Treo/Flu group (HR = 2.004; 95% CI, 1.09-3.67; p = 0.024). Overall survival, non-relapse mortality, and chronic GVHD were not significantly impacted by the specific regimen used. The choice of either FLAMSA/TBI, FLAMSA/Bu, or Treo/Flu results in no major impact on survival of older AML patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022793
003      
CZ-PrNML
005      
20240528140501.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41409-018-0288-0 $2 doi
035    __
$a (PubMed)30087463
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Sheth, Vipul $u Department of Hematology and Stem Cell Transplant, Kings College Hospital, London, London, UK.
245    10
$a Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis / $c V. Sheth, M. Labopin, J. Canaani, L. Volin, A. Brecht, A. Ganser, J. Mayer, H. Labussière-Wallet, J. Bittenbring, R. Shouval, B. Savani, M. Mohty, A. Nagler,
520    9_
$a FLAMSA followed by sequential reduced intensity conditioning and treosulfan/fludarabine are frequently used conditioning approaches used in centers of the European Society for Blood and Marrow Transplantation (EBMT) for older patients with acute myeloid leukemia (AML). It is currently unknown whether any of these regimens is superior to the others in terms of disease control and toxicity. Using the Acute Leukemia Working Party/EBMT multicenter registry we compared the outcomes of AML patients 45-65 of age transplanted between the years 2007 and 2016. A total of 629 patients were included in the analysis: 281 in the Treo/Flu group, 203 in the FLAMSA/TBI group, and 145 in the FLAMSA/Busulfan group. In multivariate analysis, FLAMSA/TBI conditioned patients had a decreased risk of relapse (hazard ratio (HR) = 0.43; 95% confidence interval (CI), 0.25-0.75; p = 0.002) and superior leukemia-free survival (HR = 0.67; 95% CI, 0.45-0.98; p = 0.042) compared to Treo/Flu conditioned patients. Rates of acute graft-versus-host disease (GVHD) were significantly higher in the FLAMSA/TBI group compared to the Treo/Flu group (HR = 2.004; 95% CI, 1.09-3.67; p = 0.024). Overall survival, non-relapse mortality, and chronic GVHD were not significantly impacted by the specific regimen used. The choice of either FLAMSA/TBI, FLAMSA/Bu, or Treo/Flu results in no major impact on survival of older AML patients.
650    _2
$a senioři $7 D000368
650    _2
$a busulfan $x analogy a deriváty $x farmakologie $x terapeutické užití $7 D002066
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a transplantace hematopoetických kmenových buněk $x metody $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a akutní myeloidní leukemie $x farmakoterapie $x mortalita $x terapie $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a míra přežití $7 D015996
650    _2
$a příprava pacienta k transplantaci $x metody $7 D019172
650    _2
$a vidarabin $x analogy a deriváty $x farmakologie $x terapeutické užití $7 D014740
655    _2
$a časopisecké články $7 D016428
700    1_
$a Labopin, Myriam $u EBMT Paris Office, CEREST-TC, Department of Hematology, Saint Antoine Hospital, Paris, France.
700    1_
$a Canaani, Jonathan $u Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Volin, Liisa $u Stem Cell Transplantation Unit, HUCH Comprehensive Cancer Center, Helsinki, Finland.
700    1_
$a Brecht, Arne $u Deutsche Klinik fuer diagnostik, KMT Zentrum, Weisbaden, Germany.
700    1_
$a Ganser, Arnold $u Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
700    1_
$a Mayer, Jiri $u Department of Internal Medicine, Hematooncology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Labussière-Wallet, Hélène $u Center Hospitalier Lyon Sud, Pavillon Marcel Bérard -Bat 1G, Service Hematologie, Lyon, France.
700    1_
$a Bittenbring, Jörg $u Department of Internal Medicine, BMT Unit, University of Saarland University Hospital, Homburg, Germany.
700    1_
$a Shouval, Roni $u Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Savani, Bipin N. $u Department of Hematology and Stem Cell Transplant, Vanderbilt University, Nashville, TN, USA. $7 xx0317726
700    1_
$a Mohty, Mohamad $u EBMT Paris Office, CEREST-TC, Department of Hematology, Saint Antoine Hospital, Paris, France. $7 xx0317729
700    1_
$a Nagler, Arnon $u EBMT Paris Office, CEREST-TC, Department of Hematology, Saint Antoine Hospital, Paris, France. arnon.nagler@sheba.health.gov.il. Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel. arnon.nagler@sheba.health.gov.il.
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 54, č. 4 (2019), s. 531-539
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30087463 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20240528140458 $b ABA008
999    __
$a ok $b bmc $g 1595112 $s 1113469
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 54 $c 4 $d 531-539 $e 20180807 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace